Aptus Capital Advisors LLC Purchases New Position in Sanofi (NASDAQ:SNY)

Aptus Capital Advisors LLC acquired a new position in shares of Sanofi (NASDAQ:SNY) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,218 shares of the company’s stock, valued at approximately $205,000.

Other hedge funds also recently modified their holdings of the company. International Assets Investment Management LLC bought a new stake in shares of Sanofi during the fourth quarter worth $4,704,000. Benjamin F. Edwards & Company Inc. grew its holdings in Sanofi by 314.7% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 9,210 shares of the company’s stock worth $458,000 after acquiring an additional 6,989 shares during the last quarter. Merit Financial Group LLC bought a new position in shares of Sanofi in the fourth quarter worth about $256,000. U.S. Capital Wealth Advisors LLC lifted its position in shares of Sanofi by 46.3% during the fourth quarter. U.S. Capital Wealth Advisors LLC now owns 7,951 shares of the company’s stock worth $395,000 after purchasing an additional 2,515 shares in the last quarter. Finally, National Bank of Canada FI grew its stake in shares of Sanofi by 1.5% during the fourth quarter. National Bank of Canada FI now owns 338,899 shares of the company’s stock valued at $16,938,000 after purchasing an additional 4,909 shares during the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on SNY. Argus upped their price objective on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, July 26th. StockNews.com upgraded Sanofi from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Sanofi has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Stock Performance

Shares of Sanofi stock opened at $58.53 on Thursday. The firm has a fifty day moving average of $52.43 and a two-hundred day moving average of $49.67. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The stock has a market capitalization of $148.24 billion, a price-to-earnings ratio of 29.41, a PEG ratio of 1.60 and a beta of 0.60. Sanofi has a 52 week low of $42.63 and a 52 week high of $58.97.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.05. The firm had revenue of $10.75 billion for the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The company’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.95 earnings per share. As a group, equities research analysts predict that Sanofi will post 4.23 EPS for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.